Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing – Animal or plant cell
Reexamination Certificate
2006-10-03
2006-10-03
Coe, Susan D. (Department: 1654)
Drug, bio-affecting and body treating compositions
Whole live micro-organism, cell, or virus containing
Animal or plant cell
C424S085200, C435S326000
Reexamination Certificate
active
07115259
ABSTRACT:
The invention is generally related to methods of treating autoimmune diseases, including both antibody-mediated and cell-mediated disorders.
REFERENCES:
patent: 6228359 (2001-05-01), Horwitz
patent: 6358506 (2002-03-01), Horwitz
patent: 6406696 (2002-06-01), Bluestone
patent: 6447765 (2002-09-01), Horwitz
patent: 6797267 (2004-09-01), Horwitz
patent: 2002/0034500 (2002-03-01), Levings et al.
patent: 2003/0039650 (2003-02-01), Gruenberg
patent: 0 497 275 (1992-08-01), None
patent: 1 241 249 (2001-03-01), None
patent: 2 824 567 (2001-05-01), None
patent: 10295368 (1998-11-01), None
patent: 11127851 (1999-05-01), None
patent: 2000212200 (2000-08-01), None
patent: WO 93/17698 (1993-09-01), None
patent: WO 97/42324 (1997-11-01), None
patent: WO 99/25366 (1999-05-01), None
patent: WO 99/48524 (1999-09-01), None
patent: WO 00/00587 (2000-01-01), None
patent: WO 00/42856 (2000-07-01), None
patent: WO 00/66158 (2000-11-01), None
patent: WO 01/16296 (2001-03-01), None
patent: WO 01/77299 (2001-10-01), None
Anasetti et al., “Treatment of acute graft-versus-host disease with a nonmitogenic anti-CD3 monoclonal antibody”, Transplantation 54:844-851 (1992).
Asai O, et al., “Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation,” Journal of Clinical Investigation 101(9):1835-1842 (1998).
Asano M, et al., “Autoimmune disease as a consequence of developmental abnormality of a T cell subpopulation.” J Exp Med. Aug. 1, 1996;184(2):387-96.
Auchincloss, Hugh Jr., et al, in Fundamental Immunology 4th Ed., Paul, W.E. (ed.) Lippincot-Raven: Philadelphia New York; 1999 pp. 1182-1222.
Barker et al., “Identification of multiple and distinct CD8+ T cell suppressor activities: dichotomy between infected and uninfected individuals, evolution with progression of disease, and sensitivity to gamma irradiation,” J Immunol 156:4476-4483 (1996).
Betz, M. and Fox, B.S., “Prostaglandin E2 inhibits production of Th1 lymphokines but not of Th2 lymphokines,” J Immunol. Jan. 1, 1991;146(1):108-13.
Blazar et al., “Both CD4+ and CD8+ T Cells Can Cause Accelerated GVHD Lethality in the Presence of High In Vivo Doses of Exogenous III10: Role of Interfereon Gamma (IFN) in GVHD Induction,” Blood 88:247 (1996) (abstract).
Blazar et al., “FK506 inhibits graft-versus-host disease and bone marrow graft rejection in murine recipients of MHC disperate donor grafts by interfering with mature peripheral T cell expansion post-transplantation”, J. Immunol 153:1836-1846 (1994).
Blazar et al., “Murine recipients of fully mismatched donor marrow are protected from lethal graft-versus-host disease by the in vivo administration of rapamycin but develop an autoimmune-like syndrome”, J. Immunol 151:5726-5741 (1993).
Blazar et al., “Recent advances in graft-versus-host disease(GVHD)”, Immunol Rev 157:79-90 (1997).
Bonig H, et al., “Transforming growth factor-beta1 suppresses interleukin-15-mediated interferon-gamma production in human T lymphocytes.” Scand J Immunol. Dec. 1999;50(6):612-8.
Bonini et al., HSY-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia, Science 276:1719-1724 (1997).
Border et al., “Transforming growth factor-beta in disease: the dark side of tissue repair,” J Clin Invest 90:1-7 (1992).
Boussiotis et al., “B7 but not intercellular adhesion molecule-1 costimulation prevents the induction of human alloantigen-specif tolerance,” J Exp Med 178:1753-1763 (1993).
Boussiotis, “Altered T-cell receptor + CD28-mediated singnaling and blocked cell cycle progression in interleukin 10 and transforming growth factor—treated alloreactive T cells that do not induce graft-versus-host disease,” Blood 97:565-571 (2001).
Bucy, R.P. et al., FASEB J. 1995 9:A497 (Abstract).
Chandrasekar, B., et al., “Dietary calorie restriction inhibits transforming growth factor-beta (TGF-beta) expression in murine lupus nephritis”, 9th International Congress on Immunology, 848 (1995) (Abstract).
Chavin, et al., “Anti-CD2 mAbs Suppress Cytotoxic Lymphocyte Activity by the Generation of Th2 Suppressor Cells and Receptor Blockade,” J Immunol 152:3729-3739 (1994).
Chen W, et al., “T cells specific for a polymorphic segment of CD 45 induce graft-versus-host disease with predominant pulmonary vasculitis.” J Immunol. Jul. 15, 1998;161(2):909-18.
Chong P. et al. “Inhibition of protein-kinase C in peripheral blood mononuclear cells of patients with systemic lupus erythematosus: effect on spontaneous immunoglobulin production,” Autoimmunity, 10:227-231 (1991).
Cosimi, A.B., et al., “Treatment of acute renal allograft rejection with OKT3 monoclonal antibody,” Transplantation. Dec. 1981;32(6):535-9.
Delgiudice, G., et al., “TGF-beta activity is increased in systemic lupus erythematosus (SLE) and progressive systemic sclerosis (PSS)”, Arthritis and Rheumatism vol. 36 (9 Suppl.) p. S 196(Sep. 1993).
Dooms, H. et al., “IL-2 and IL-15 direct the outcome of inappropriate CD4+ T cell stimulation towards apoptosis and anergy respectively,” European Cytokine Network, 9(3): 169 (1998).
Dumont et al., “Distinct Mechanisms of Suppression of Murine T Cell Activation by the Related macrolides FK-506 and Rapamycin”, J. Immunol 144:251-258 (1990).
Dupont, B., “Immunology of hematopoietic stem cell transplantation: a brief review of its history”, Immunol Reviews 157:5-12 (1997).
Early E, and Reen DJ. “Rapid conversion of naive to effector T cell function counteracts diminshed primary human newborn T cell responses.” Clin Exp Immunol. Jun. 1999;116(3):527-33, (Abstract).
FAST, “Generation and characterization of IL-2-activated veto cells”, J Immunol. 149:1510-1515( 1992).
Fernandes, G., et al., “Calorie restriction delays autoimmune murine lupus by differentially modulating oncogenes and TGF-beta-1 expression”, 9th International Congress on Immunology., 848 (1995).(Abstract).
Fowler et al., “Donor CD4-enriched cells of Th2 cytokine phenotype regulate graft-versus-host disease without impairing allogeneic engraftment in sublethally irradiated mice”, Blood 84:3540-3549 (1994).
Gao Q, et al., “CD4+CD25+ cells regulate CD8 cell anergy in neonatal tolerant mice.” Transplantation. Dec. 27, 1999;68(12):1891-7.
Garderet L, et al., “Effective depletion of alloreactive lymphocytes from peripheral blood mononuclear cell preparations.” Transplantation. Jan. 15, 1999;67(1):124-30.
Goldman et al., “Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk for relapse associated with T-cell depletion”, Ann Intern Med 108:806-814 (1988).
Gratama et al., “Treatment of Acute Graft-Versus-Host Disease With Monoclonal Antibody OKT3. Clinical results and effect on circulating T lymphocytes”, Transplantation 38(5):469-474 (1984).
Gray et al., “The role of transforming growth factor beta in the generation of suppression: an interaction between CD8+ T and NK cells”, J Exp Med 180:1937-1942 (1994).
Gray et al., “Activated Natural Killer Cells Can Induce Resting B Cells to Produce Immunoglobulin,” Arthritis & Rheumatism, 37(9)suppl:S378 (1994).
Gray, J. D., et al., “Generation of an Inhibitory Circuit Involving CD8+ T Cells, IL-2, and NK Cell-Derived TGF-β: Contrasting Effects of Anti-CD2 and Anti-CD3”, J Immunol., 160:2248-2254 (1998).
Gribben et al., “Complete blockade of B7 family-mediated costimulation is necessary to induce human alloantigen-specific anergy: a method to ameliorate graft-versus-host disease and extend the donor pool”, Blood 97:4887-4893 (1996).
Groux, H., et al., “A CD4+ T-cell subset inhibits antigen-specific T-ce
Bernhardt Jeffery P.
Coe Susan D.
Dorsey & Whitney LLP
Trecartin Richard F.
University of Southern California
LandOfFree
Use of cytokines and mitogens to inhibit pathological immune... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of cytokines and mitogens to inhibit pathological immune..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of cytokines and mitogens to inhibit pathological immune... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3643449